Is Wave Life Sciences Ltd. (WVE) a Buy, Sell, or Hold?
Wave Life Sciences Ltd.
NASDAQ:WVE
$6.035 USD
-$0.09 (-1.55%)
- Volume
- 310.61K
- Average Volume
- 3.84M
- Market Capitalization
- $1.16B
- P/E Ratio
- -5.69
- Dividend Yield
- 0.00%
- Price Target
- $15.00
- Year High
- $21.73
- Year Low
- $5.02
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $11.26
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Paul Bolno |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | WVE |
| CUSIP | Y95308105 |
| CIK | 0001631574 |
| Web | https://wavelifesciences.com |
| Phone | 65 6236 3388 |
| Currency | USD |
| Employees | 317 |
| Country | SG |
Liquidity
| Debt-to-Equity Ratio | 0.03 |
| Payout Ratio | 0.00 |
| Current Ratio | 11.26 |
| Quick Ratio | 11.26 |
| Cash Ratio | 10.93 |
Sales & Book Value
| Annual Sales | $42.73M |
| Price / Sales | 16.17 |
| Cash Flow | -0.92 |
| Price / Cash Flow | -6.33 |
| Price / Book | 2.36 |
Price Target and Rating
| Average Stock Price Forecast | $15.00 |
| High Stock Price Forecast | $43.00 |
| Low Stock Price Forecast | $13.00 |
| Forecast Upside/Downside | -59.77% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 25 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.21 |
| Trailing P/E Ratio | -5.69 |
| PEG Ratio | 0.10 |
| P/E Growth | 0.10 |
| Net Income | $-204.38M |
| Net Margin | -255.70% |
| Pretax Margin | -255.70% |
| Return on Equity | -56.41% |
| Return on Assets | -31.46% |
Financials Score
| AltmanZ Score | 6.46 |
| Piotroski Score | 3.00 |
| Working Capital | 511.44M |
| Total Assets | 583.54M |
| Ebit | -183.59M |
| Market Cap | 1.14B |
| Total Liabilities | 71.81M |
Poll Results
About Wave Life Sciences Ltd. (NASDAQ:WVE) Stock
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne ... muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
2026-07-07 16:15:00
CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), has obtained the requisite shareholder approval required in connection with its proposed redomiciliation (“Redomiciliation”) to the United States by way of the implementation of a statutory procedure known as a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “Scheme of Arrangement”). The Scheme of Arrangement remains subject to approval by the High Court of the Republic of Singapore (the “Singapore Court”).
Does Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect?
2026-07-01 10:55:14
The consensus price target hints at a 294.7% upside potential for Wave Life Sciences (WVE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2026-06-24 08:30:00
In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing
Wave Life Sciences (WVE) Upgraded to Buy: Here's Why
2026-06-16 13:02:24
Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2026-06-08 10:58:32
Wave Life Sciences Ltd. (WVE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Wave Life Sciences to Present at Upcoming Investor Conferences
2026-06-01 08:30:00
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave's management team are scheduled to participate in two upcoming investor conferences in June.
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter
2026-05-31 15:56:27
This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform.
2026-05-27 08:41:00
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Wave Life Sciences Ltd. (NASDAQ: WVE) or certain of its executive officers violated federal securities laws. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.
Frequently Asked Questions
-
What is the current Wave Life Sciences Ltd. (WVE) stock price?
-
Wave Life Sciences Ltd.(NASDAQ:WVE) stock price is $6.035 in the last trading session. During the trading session, WVE stock reached the peak price of $21.73 while $5.02 was the lowest point it dropped to. The percentage change in WVE stock occurred in the recent session was --1.55% while the dollar amount for the price change in WVE stock was -$-0.09.
-
WVE's industry and sector of operation?
-
The NASDAQ listed WVE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of WVE?
-
Chandra Vargeese | Chief Technology Officer
Erik Ingelsson | Chief Scientific Officer
Gregory L. Verdine | Founder & Director
Paul Bolno | President, Chief Executive Officer & Director
Kyle Moran | Chief Financial Officer & Principal Accounting Officer -
How many employees does WVE have?
-
Number of WVE employees currently stands at 317. WVE operates from Marina One East Tower, Singapore, CE 018936, SG.
-
Link for WVE official website?
-
Official Website of WVE is: https://wavelifesciences.com
-
How do I contact WVE?
-
WVE could be contacted at phone #65 6236 3388 and can also be accessed through its website. WVE operates from Marina One East Tower, Singapore, CE 018936, SG.
-
How many shares of WVE are traded daily?
-
The average number of WVE shares traded daily for last 3 months was 3.84M.
-
What is the market cap of WVE currently?
-
The market value of WVE currently stands at $1.16B with its latest stock price at $6.035